A Passage to optimal CNS vectors

Passage uses James Wilson’s AAV vectors, gene therapies targeting the CNS

Passage is arming itself with AAV vectors, gene therapies and non-human primate studies from gene therapy pioneer James Wilson at UPenn to develop disease-modifying treatments for rare monogenic diseases affecting the CNS. The company launched last month with a $115.5 million series A round led by OrbiMed Advisors.

Passage Bio Inc. co-founder and interim CEO Stephen Squinto told BioCentury that most other companies in

Read the full 633 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE